A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Sulfamerazine
Magnesium citrate
The risk or severity of adverse effects can be increased when Magnesium citrate is combined with Sodium phosphate, dibasic.
Sulfamerazine
Methylcellulose
The risk or severity of adverse effects can be increased when Methylcellulose is combined with Sodium phosphate, dibasic.
Sulfamerazine
Docusate
The risk or severity of adverse effects can be increased when Docusate is combined with Sodium phosphate, dibasic.
Sulfamerazine
Mineral oil
The risk or severity of adverse effects can be increased when Mineral oil is combined with Sodium phosphate, dibasic.
Sulfamerazine
Lactitol
The risk or severity of adverse effects can be increased when Lactitol is combined with Sodium phosphate, dibasic.
Sulfamerazine
Sennosides
The risk or severity of adverse effects can be increased when Sennosides is combined with Sodium phosphate, dibasic.
Sulfamerazine
Castor oil
The risk or severity of adverse effects can be increased when Castor oil is combined with Sodium phosphate, dibasic.
Sulfamerazine
Plantago seed
The risk or severity of adverse effects can be increased when Plantago seed is combined with Sodium phosphate, dibasic.
Sulfamerazine
Carboxymethylcellulose
The risk or severity of adverse effects can be increased when Carboxymethylcellulose is combined with Sodium phosphate, dibasic.
Sulfamerazine
Polycarbophil
The risk or severity of adverse effects can be increased when Polycarbophil is combined with Sodium phosphate, dibasic.
Sulfamerazine
Picosulfuric acid
The risk or severity of adverse effects can be increased when Picosulfuric acid is combined with Sodium phosphate, dibasic.
Sulfamerazine
Bisacodyl
The risk or severity of adverse effects can be increased when Bisacodyl is combined with Sodium phosphate, dibasic.
Sulfamerazine
Oxyphenisatin
The risk or severity of adverse effects can be increased when Oxyphenisatin is combined with Sodium phosphate, dibasic.
Sulfamerazine
Dantron
The risk or severity of adverse effects can be increased when Dantron is combined with Sodium phosphate, dibasic.
Sulfamerazine
Sorbitol
The risk or severity of adverse effects can be increased when Sorbitol is combined with Sodium phosphate, dibasic.
Sulfamerazine
Alcuronium
The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Alcuronium.
Sulfamerazine
Gallamine
The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Gallamine.
Sulfamerazine
Atracurium
The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Atracurium.
Sulfamerazine
Hexamethonium
The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Hexamethonium.
Sulfamerazine
Gantacurium
The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Gantacurium.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3